Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression

RECOMMENDED

Cardiovascular Risk and Diseases

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Heart Assoc.

Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B

doi: 10.1161/JAHA.119.014908.

COMMENTED

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended and commented by Prof. Dr emer. Josef Flammer, Faculty Member

BMJ

Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM

doi: 10.1136/bmj.m4573

Cardiovascular Risk and Diseases

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Lancet Diabetes Endocrinol

Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC

doi: 10.1016/S2213-8587(21)00203-5

RECOMMENDED

Therapy and InterventionFurther Publications

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP

doi: 10.1001/jamacardio.2020.4511

Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

N Engl J Med.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK1, Sattar N, Rosengren A, Gudbjörnsdottir S

doi: 10.1056/NEJMoa1608664.

Cardiovascular Risk and Diseases

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Cardiovasc Diabetol

Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J

doi: 10.1186/s12933-021-01323-5

Cardiovascular Risk and Diseases

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials

Eur Heart J.

Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P

doi: 10.1093/eurheartj/ehaa082.

Lipid-Lowering DrugsTherapy and Intervention

Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Circulation

Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, Baek S, Gerstein HC

doi: 10.1161/CIRCULATIONAHA.121.057934

Heart Failure

Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure

JAMA Cardiol.

Bassi NS, Ziaeian B, Yancy CW, Fonarow GC

doi: 10.1001/jamacardio.

Related content

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials

Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure